James is a Senior Associate on the Life Sciences team and focuses on identifying and evaluating new investment opportunities.
James joined the Frazier Life Sciences team in 2022, where he focuses on identifying and evaluating new investment opportunities.
Prior to joining Frazier, James led the translational medicine efforts at Forty Seven Inc. (acquired by Gilead Sciences Inc. in 2020), a clinical-stage biotech company targeting CD47 in multiple oncology indications, as the Director of Translational Medicine. In addition, he did his postgraduate training in Internal Medicine at Massachusetts General Hospital in Boston and his Oncology fellowship at Stanford Medicine.
James completed the Medical Scientist Training Program at Stanford University School of Medicine, where he received his M.D, and Ph.D. in Stem Cell Biology and Regenerative Medicine. Prior to his medical training, he completed his B.S. in Microbiology, Immunology, and Molecular Genetics at the University of California Los Angeles where he graduated summa cum laude and was a Beckman Scholar.